Browse studies

Find your next paid study

17 recruiting studies matching your filters

Sequencing-guided cHemotherapy Optimization Using Real-Time Evaluation in Newly Diagnosed DLBCL With Circulating Tumor DNA: SHORTEN-ctDNA

The purpose of this study is to 1) determine whether it is feasible to measure circulating tumor DNA (ctDNA) in real-time during standard treatment for newly d…

LymphomaLymphoma, B-CellDiffuse Large B Cell Lymphoma+2 more

Estimated

~$10 – $7,500

Hua-Jay J Cherng, MDNCT06693830

Phase 1

A Phase 1b Open-Label Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

The primary objective of this study is to determine the recommended dosing regimen of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) or high-g…

Diffuse Large B-Cell LymphomaHigh-grade B-cell Lymphoma

Estimated

~$10 – $8,750

ADC Therapeutics S.A.NCT05660395

Phase 1

A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administ…

B Cell LymphomaNHL, AdultMantle Cell Lymphoma+23 more

Estimated

~$10 – $8,750

Phase 2

A Phase 2 Trial of Emapalumab for the Prevention of CAR-T Cell Associated Toxicities

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-…

Large B-cell LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+4 more

Estimated

~$10 – $7,500

Marcela V. Maus, M.D.,Ph.D.NCT06550141

Phase 1

A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side eff…

Non-hodgkin LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+7 more

Estimated

~$10 – $7,500

Marcela V. Maus, M.D.,Ph.D.NCT06026319